What's Going On With Annovis Shares Today?
Portfolio Pulse from Nabaparna Bhattacharya
Annovis Bio, Inc. (NYSE:ANVS) shares are gaining in premarket trading following a 76% increase in the previous session. The company announced positive data from its Phase III Parkinson’s study, showing improvements in the Unified Parkinson’s Disease Rating Scale with its treatment, buntanetap. Additionally, Annovis filed a provisional patent for the manufacturing process of new solid forms of buntanetap.
July 03, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Annovis Bio shares are gaining in premarket trading after a 76% increase in the previous session. The company announced positive Phase III Parkinson’s study results and filed a provisional patent for the manufacturing process of new solid forms of buntanetap.
The positive Phase III study results and the new patent filing are significant milestones for Annovis Bio, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100